Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stock Report

Market Cap: US$9.8b

Kymera Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:KYMR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
29 Jun 26SellUS$59,884,937Atlas Venture Advisors, Inc.Company544,528US$118.66
26 Jun 26SellUS$173,665,077BVF Partners L.P.Company1,630,658US$106.50
22 Jun 26SellUS$24,268,861Atlas Venture Advisors, Inc.Company246,330US$102.48
26 May 26SellUS$317,922Jeremy ChadwickIndividual4,054US$79.17
09 Apr 26SellUS$284,037Noah GoodmanIndividual3,264US$87.11
04 Mar 26SellUS$1,091,231Bruce JacobsIndividual12,471US$89.66
04 Mar 26SellUS$916,669Jared GollobIndividual10,508US$89.66
04 Mar 26SellUS$515,594Jeremy ChadwickIndividual5,958US$89.66
12 Dec 25SellUS$21,699,044Atlas Venture Advisors, Inc.Company236,588US$93.20
11 Dec 25BuyUS$172,499,918Baker Bros. Advisors LPCompany2,005,813US$86.00

Insider Trading Volume

Insider Buying: KYMR insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of KYMR?
Owner TypeNumber of SharesOwnership Percentage
Private Companies6,4430.00659%
Individual Insiders957,4970.979%
Hedge Funds16,131,98916.5%
Institutions80,659,64382.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.

Top Shareholders

Top 25 shareholders own 97.69% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.9%
FMR LLC
12,348,295US$1.4b5.55%0.06%
13.9%
T. Rowe Price Group, Inc.
11,525,844US$1.4b69.8%0.09%
10.4%
Baker Bros. Advisors LP
8,657,242US$1.0b0%4.74%
8.99%
Avoro Capital Advisors LLC
7,474,747US$877.5m0%9.25%
6.66%
BlackRock, Inc.
5,538,210US$650.1m9.43%0.01%
4.68%
Wellington Management Group LLP
3,889,687US$456.6m-11.9%0.06%
4.66%
BVF Partners L.P.
3,872,052US$454.5m-29.6%11.5%
4.07%
Vanguard Capital Management, LLC
3,382,109US$397.0m2.25%0.01%
3.6%
Vanguard Portfolio Management, LLC
2,992,193US$351.3m4.11%0.01%
3.53%
Artal Group S.A.
2,935,830US$344.6m-7.88%4.89%
3.42%
Atlas Venture Advisors, Inc.
2,847,541US$334.3m-37.8%42.3%
3.29%
State Street Investment Management
2,737,226US$321.3m14.5%0.01%
2.18%
Geode Capital Management, LLC
1,816,331US$213.2m10.4%0.01%
2.1%
UBS Asset Management AG
1,744,643US$204.8m-8.16%0.01%
1.67%
Capital Research and Management Company
1,388,881US$163.0m-17%0.01%
1.26%
Driehaus Capital Management LLC
1,043,583US$122.5m-2.4%0.51%
1.07%
AllianceBernstein L.P.
888,035US$104.2m-6.73%0.03%
1.01%
Holocene Advisors, LP
836,759US$98.2m9.93%0.2%
0.94%
The Goldman Sachs Group, Inc.
778,411US$91.4m0%0.02%
0.93%
MRL Ventures Fund LLC
772,165US$90.6m0%28.67%
0.91%
Frontier Capital Management Co LLC
759,848US$89.2m19.5%0.72%
0.91%
Norges Bank Investment Management
757,246US$88.9m4,480%no data
0.9%
Commodore Capital LP
750,000US$88.0m0%3.55%
0.9%
Federated Hermes, Inc.
749,398US$88.0m39.6%0.12%
0.9%
Dimensional Fund Advisors LP
745,152US$87.5m25.7%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/16 02:03
End of Day Share Price 2026/08/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kymera Therapeutics, Inc. is covered by 39 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Eliana MerleBarclays
Zhiqiang ShuBerenberg